pharma
MSD’s Keytruda improvess overall survival in Phase 3 oesophageal cancer
November 15, 2018Research and Development Cancer, MSD, PD-L1, keytruda, pharma
MSD has announced new Phase 3 data on its anti-PD-1 therapy Keytruda (pembrolizumab) as a second-line treatment for advanced or …
Phamaceutical trade lobby responds to Brexit deal
November 15, 2018Business Services, Medical Communications, Research and Development ABPI, brexit, negotiations, pharma, politics
The Association of the British Pharmaceutical Industry (ABPI) has responded to Theresa May’s Brexit deal, after the government announced a …
Pfizer defeated in Britain’s highest court over Lyrica patent
November 15, 2018Business Services, Medical Communications Legislation, Lyrica, Pfizer, court, pharma
American pharma firm Pfizer have lost in the final round of a protracted court battle over the patent on epilepsy …
3 in 4 UK diabetes patients suffer from mental health issues, says report
November 14, 2018Medical Communications, Research and Development UK, World Diabetes Day, diabetes, pharma
To mark this year’s World Diabetes Day on 14 November, a new report has shed more light on the psychological …
Novartis’ Entresto tops enalapril in stabilised heart failure patients
November 13, 2018Manufacturing and Production, Research and Development Entresto, Novartis, cardiovascular, enalapril, heart failure, pharma
Novartis has declared new findings for Entresto (sacubitril/valsartan) at the American Heart Association’s (AHA) scientific sessions, showing that the drug proved …
Azacitidine and nivolumab combo proves successful in phase II trial
November 13, 2018Manufacturing and Production Cancer, leukaemia, opdivo, pharma, texas
A combination of chemotherapy drug azacitidine and nivolumab (Bristol-Myers Squibb’s Opdivo) has proven effective in treating patients with relapsed or …
AstraZeneca sells off paediatric lung infection drug to Sobi for $1.5bn
November 13, 2018Manufacturing and Production, Sales and Marketing AstraZeneca, Synagis, espiratory syncytial virus, pharma, sobi
AstraZeneca has jettisoned another non-essential asset with the sale of Synagis (palivizumab), a preventative treatment for infections relating to respiratory …
Samsung Biologics shares fall by 20% after Korean investigation
November 13, 2018Manufacturing and Production Shares, accounting, pharma, smasung biologics, stockmarket
Shares in Korean firm Samsung BioLogics plummeted this week, falling by as much as 20% on Monday, after the South …
MSD’s Keytruda chalks up FDA approval in liver cancer
November 12, 2018Sales and Marketing Cancer, FDA, US, hepatocellular carcinoma, keytruda, pharma
MSD’s blockbuster immunotherapy Keytruda has secured another FDA approval, this time for the treatment of hepatocellular carcinoma (HCC) in patients …
AZ’s Farxiga shows strength in largest ever SGLT2 inhibitor cardiovascular outcomes study
November 12, 2018Research and Development, Sales and Marketing AstraZeneca, cardiovascular, farxiga, pharma
AstraZeneca has revealed new data for its sodium-glucose co-transporter 2 (SGLT2) inhibitor Farxiga (dapagliflozin) at the American Heart Association (AHA) …
No-deal Brexit preparations are a waste of time and money, according to Welsh industry representatives
November 12, 2018Sales and Marketing ABPI, brexit, no-deal, pharma, stockpiling
The UK government’s request that pharmaceutical companies stockpile an additional six weeks’ worth of medicine, in preparation for a no-deal …
Eisai’s Lenvima wins over NICE in liver cancer in just three months
November 9, 2018Medical Communications, Sales and Marketing Cancer, Eisai, Lenvima, Levantinib, NHS, NICE, UK, liver cancer, pharma
Eisai has revealed that its multireceptor Tyrosine Kinase Inhibitor Lenvima (lenvatinib) has been recommended by NICE, meaning it can now …
NICE fail to recommend AstraZeneca’s cancer drug Olaparib on cost effectiveness basis
November 9, 2018Medical Communications, Sales and Marketing AstraZeneca, NHS, NICE, UK, olaparib, pharma
Britain’s cost effectiveness body the National Institute of Health and Care Excellence (NICE) has chosen not to recommend AstraZeneca’s Olaparib …
NHS diabetes prescriptions top £1 billion a year
November 9, 2018Medical Communications, Sales and Marketing Health Education England, NHS, UK, diabetes, pharma
The NHS in England is now spending over £1billion a year on diabetes prescriptions, almost doubling in the last decade, …
Jazz Pharma’s Vyxeos secures NICE recommendation in acute myeloid leukaemia
November 8, 2018Sales and Marketing Cancer, NHS, NICE, UK, Vyxeos, acute myeloid leukaemia, jazz pharmaceuticals, pharma
Jazz Pharmaceuticals has revealed that NICE has chosen to recommend that its 44mg/100mg powder formulation of Vyxeos for concentrate for …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
